Novo Nordisk’s CagriSema Shows 12.4% Weight Loss in Reimagine 5 Trial

The headline number lands below the weight-loss bar set by the most potent injectables already on the market, which matters more for Novo's competitive positioning than for the mechanism itself. The disclosure is also thin: without tolerability, discontinuation or trial-population detail, the efficacy figure alone can't be read as a clean win or loss. Whether CagriSema's profile improves in the remaining readouts, and how payers weigh incremental efficacy against cost, is the open question.